Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA) from its SEC filings: 2025 revenue $9.8 million (+17% vs the year before), net margin -1115%, free cash flow -$93.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $9.8 million |
| Revenue growth | +17% |
| Net income | -$109.0 million |
| Net margin | -1115.3% |
| Free cash flow | -$93.8 million |
| Diluted EPS | $-0.34 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $455.4 million |
| Long-term debt | $49.3 million |
| Share count, 1 year | +19% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.